{
    "ticker": "ABEO",
    "name": "Abeona Therapeutics Inc.",
    "description": "Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for severe genetic diseases and cancer. Founded in 2013, Abeona is dedicated to advancing innovative treatments that address unmet medical needs, particularly in the fields of genetic disorders such as Sanfilippo syndrome and epidermolysis bullosa. The company\u2019s proprietary platform leverages a combination of gene therapy and cell therapy approaches to deliver transformative treatments. Abeona\u2019s lead product candidates include ABO-101, aimed at treating Sanfilippo syndrome type A, and EB-101, a cell therapy for the treatment of recessive dystrophic epidermolysis bullosa. With a strong commitment to research and development, Abeona collaborates with leading academic institutions and industry partners to enhance its therapeutic offerings. The company is also focused on advancing its clinical trials and expanding its pipeline to provide patients with innovative solutions that improve their quality of life. Abeona Therapeutics is headquartered in Cleveland, Ohio, and strives to be a leader in the biopharmaceutical industry by utilizing cutting-edge science and technology to bring hope to patients with rare diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cleveland, Ohio, USA",
    "founded": "2013",
    "website": "https://www.abeonatherapeutics.com",
    "ceo": "Timothy J. Miller",
    "social_media": {
        "twitter": "https://twitter.com/AbeonaTx",
        "linkedin": "https://www.linkedin.com/company/abeona-therapeutics/"
    },
    "investor_relations": "https://investors.abeonatherapeutics.com",
    "key_executives": [
        {
            "name": "Timothy J. Miller",
            "position": "CEO"
        },
        {
            "name": "Steven H. Rouhandeh",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "ABO-101"
            ]
        },
        {
            "category": "Cell Therapy",
            "products": [
                "EB-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Abeona Therapeutics Inc. | Gene and Cell Therapy for Rare Diseases",
        "meta_description": "Explore Abeona Therapeutics Inc., a leader in gene and cell therapy focused on innovative treatments for genetic diseases. Discover our pipeline and commitment to patients.",
        "keywords": [
            "Abeona Therapeutics",
            "Gene Therapy",
            "Cell Therapy",
            "Rare Diseases",
            "Sanfilippo Syndrome",
            "Epidermolysis Bullosa"
        ]
    },
    "faq": [
        {
            "question": "What is Abeona Therapeutics known for?",
            "answer": "Abeona Therapeutics is known for developing gene and cell therapies for severe genetic diseases."
        },
        {
            "question": "Who is the CEO of Abeona Therapeutics?",
            "answer": "Timothy J. Miller is the CEO of Abeona Therapeutics Inc."
        },
        {
            "question": "Where is Abeona Therapeutics headquartered?",
            "answer": "Abeona Therapeutics is headquartered in Cleveland, Ohio, USA."
        },
        {
            "question": "What are Abeona's main product candidates?",
            "answer": "Abeona's main product candidates include ABO-101 for Sanfilippo syndrome and EB-101 for epidermolysis bullosa."
        },
        {
            "question": "When was Abeona Therapeutics founded?",
            "answer": "Abeona Therapeutics was founded in 2013."
        }
    ],
    "competitors": [
        "BLUE",
        "SGMO",
        "AVTX",
        "RGEN"
    ],
    "related_stocks": [
        "NVS",
        "PFE",
        "MRK",
        "ABBV"
    ]
}